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Abstract
Background: Following an AMI, it is important for patients and their physicians to appreciate the subsequent risk of death,
and the potential benefits of invasive cardiac procedures and secondary preventive therapy. Studies, to-date, have focused
largely on high-risk populations. We wished to determine the risk of death in a population-derived cohort of 2,887 patients
after a first acute myocardial infarction (AMI).
Methods: Logistic regression and survival analysis were conducted to investigate the effect of different baseline
characteristics, pharmacological therapies and revascularization procedures on coronary heart disease (CHD) and all-cause
mortality outcomes.
Results: Within five years 44.4% of patients died (27.1% short-term [,30 days] and 23.7% longer-term [$30 days]).
Percutaneous transluminal coronary angioplasty (Adjusted Hazards Ratio (AHR) = 0.49, 95% Confidence Interval (CI) 0.26–
0.93), b-blockers (AHR= 0.58, 95%CI 0.46–0.74) and statins (AHR= 0.60, 95%CI 0.47–0.77) were all associated with significant
reductions in longer-term CHD-related mortality. However, not all patients received secondary preventive therapy (8.7%).
Diabetes (AHR= 1.83, 95%CI 1.43–2.34), stroke (AHR= 1.73, 95%CI 1.35–2.22), heart failure (AHR= 1.69, 95%CI 1.28–2.22),
smoking (AHR= 1.72, 95%CI 1.18–2.51) and obesity (.30 kg/m2; AHR= 1.39, 95%CI 1.01–1.90) increased the risk of longer-
term mortality independent of other risk factors.
Conclusions: It is encouraging that the coronary procedure PTCA and pharmacological secondary prevention therapies
were found to be strongly associated with an important reduced risk of subsequent death, although not all patients
received these interventions. Smoking, being obese and having cardiovascular related disease at baseline were also
associated with an increased likelihood of longer-term mortality, independent of other baseline characteristics. Thus, the
provision of smoking cessation, advice on diet (for obese patients) and optimal treatment is likely to be crucial for reducing
mortality in all patients after AMI.
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Introduction
Coronary heart disease (CHD) continues to be the leading cause
of mortality among adults in the industrialized world [1]. For
example, it now accounts for one in three deaths in the United
States of America [2]. Following a diagnosis of acute myocardial
infarction (AMI), important concerns of both patients and their
physicians are the subsequent risk of death and whether this can be
reduced by use in real life (as opposed to clinical trials) of
appropriate medical and surgical interventions.
A large multi-national study identified a number of key
physical signs, biochemical measurements and co-morbidities,
associated with the short-term prognosis of patients admitted to
hospital for acute coronary syndrome [3]. These factors included
pulse rate, systolic blood pressure, initial serum creatinine
concentration, elevated cardiac markers, peripheral vascular
disease and heart failure. The study, however, only followed
patients for six months after their index event. Community-based
studies have attempted to determine longer-term survival,
sometimes up to five years, although selection procedures used
when identifying the different cohorts may have introduced
important biases [4–9]. Limitations have included: studies
restricted to certain age-groups [4–5]; patients with specific co-
morbidities such as diabetes [6–7]; those experiencing an
emergency admission [8]; and those who are hospitalized [9]. If
research is to inform everyday clinical practice, issues relating to
the representativeness of samples and consequent generalizability
of findings are important. A community-based perspective is
especially valuable in the increasing number of countries where
primary care helps provide primary prevention (to help reduce
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the incidence of disease and prevention of death) and much of the
long-term management of chronic disease.
This paper builds on previous work, which ascertained the five-
year prognosis of an incident cohort of people with angina using a
novel linked primary care, secondary care and mortality database
[10]. Here, we determined in routine clinical practice the five-year
risk of death from any cause and CHD after a first AMI. We also
ascertained whether this risk was modified by revascularization
procedures and pharmacological treatments taken for secondary
prevention, and (in a secondary analysis) by baseline smoking and
Body Mass Index (BMI) kg/m2.
Methods
Sampling frame
Almost all individuals resident in Scotland in the United
Kingdom are registered with a primary care practice, which
provides health care services free of charge. Virtually all specialist
hospital care services are also free of charge, usually obtained
through referral from primary care or, in emergency situations,
through patients attending an accident and emergency depart-
ment. Primary care-based physicians provide, or coordinate, much
of the care of patients discharged back into the community by
secondary and tertiary care services.
The sampling frame for this study was all patients (n = 238,064)
registered with 40 primary care practices in Scotland. Complete-
ness of capture of contacts and accuracy of clinical event coding
(using Read codes) has been found to be above 91% in these
practices [11–12]. The electronic recording of long-term prescrib-
ing information by primary care has also been found to be
accurate and complete [13]. These primary care patient data were
linked in May 2007 with deprivation scores (Scottish Index of
Multiple Deprivation) [14], hospital admission records for
National Health Service Scottish hospitals held on the Scottish
Morbidity Record (SMR) database (housed by the Information
Services Division) and certified cause of death information
collected by the General Register Office for Scotland (GROS).
The hospital data are considered to be reliable from 1981, with
completeness and accuracy rates exceeding 90% [15]. The linkage
created a novel PCCIU-SMR-GROS database. We have
previously shown that individuals on the linked database are
broadly representative of the Scottish population, with respect to
age, sex, and social deprivation [12]. Use of the de-identified
linked database for this research was approved by the Caldicott
Guardian for the Information Services Division.
Incident sample
All patients who experienced an AMI apparently for the first
time between 1st January 1997 and 31st December 2001 were
identified. This involved identifying those whose primary care
computer records contained a relevant entry of AMI (using Read
codes [16]) or those with a relevant entry on the secondary care
database (using International Classification of Diseases (ICD)
version 10 codes I21–I22). The first such event in the timeframe
was designated the index episode. The primary and secondary
care data of each identified person was then checked, for as long as
it existed, for any recording of an AMI prior to the date of the
index episode.
Baseline characteristics
The primary care computer records of incident cases were
examined for the presence of co-morbidities and risk-factors when
the index episode occurred. These co-morbidities were determined
a priori to be associated with cardiovascular disease. The postcode
of each patient was used to assign socioeconomic status on a 10-
point scale, which was then converted to quintiles for analysis
(1 =most affluent, to 5 =most deprived), based on the Scottish
Index of Multiple Deprivation, which uses 37 indicators of poverty
across seven domains (current income, employment, health,
education (including skills and training), housing, geographic
access and local crime statistics) [14].
As part of a subgroup analysis we also determined smoking
status and BMI (kg/m2) where present in the patient record. For
smoking status firstly we ascertained those that were non-smokers,
then smokers and finally ex-smokers at baseline. Patients with a
record of being a never smoker at any time on their primary care
computer records were classified as non-smokers at baseline. If a
smoking-related Read code was found prior to baseline, the
patient was considered to be a smoker. If a record of an ex-smoker
code was found subsequent to the latest smoking code and prior to
the index date, the patient was defined as an ex-smoker. Obesity
(BMI .30 kg/m2) was determined using information recorded
about BMI closest to the index episode of AMI. For 242 (8.4%)
patients this was recorded after the date of the index episode.
Follow-up
Each patient was followed from the date of the index episode to
death from any cause and from CHD (prior to 2000 ICD9: 410–4;
thereafter ICD10: I20–25, I42, I46, I50 N.B. GROS used ICD9
for coding for slightly longer than Information Services Division)
after 30 days but before five years (1,826 days, designated longer-
term mortality).
We also examined the relationship between revascularization by
Coronary Artery Bypass Grafting (CABG- Operation and
Procedures Coding System (OPCS) version 4 code: K40–5) or
Percutaneous Transluminal Coronary Angioplasty (PTCA) with or
without stents (OPCS4: K49, K75, K501, K508–9), and longer-
term mortality. In addition, we investigated associations between
the provision of secondary prevention therapies: angiotensin
converting enzyme (ACE) inhibitors, b-blockers, antiplatelets or
statins, and mortality. Information about surgical procedures and
medical treatments given was retrieved from the relevant SMR
hospital records and primary care practice prescribing and
consultation records. GROS mortality records were used to
identify those who died.
Statistical analysis
The Chi-squared test was used to test for an association between
sex and other categorical baseline characteristics (age, socioeco-
nomic status and co-morbidities). Separate statistical models were
fitted for longer-term (31 days to five years) all cause mortality and
CHD-related mortality.
Longer-term mortality. Survival analysis was conducted to
investigate the effect of different baseline characteristics on time to
all-cause and CHD-related mortality from 31 days to five years
post-AMI. The 30-day cut-off point for mortality has been used
previously [8]. We excluded patients if they died in the first 30
days of follow-up. For CHD-related mortality, patients were
censored prior to five years if they died from another cause.
Initially, separate Cox proportional hazards models were fitted for
each baseline characteristic to determine its effect on outcome.
Full models were then fitted adjusting for all potential confounders
(i.e. sex, year of age, socioeconomic status and co-morbidities).
Adjusted hazard ratios (AHR) and 95% CIs for each of the
baseline variables are presented.
The effect of having a revascularization procedure (CABG or
PTCA) and undergoing secondary prevention therapies (ACE
inhibitors, b-blockers, anti-platelets and statins) during follow-up
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on longer-term mortality was examined by including these as time
varying covariates in the survival models. Separate Cox models
were fitted for each time-varying covariate and, in an extension of
the adjusted mortality analysis, all six time-varying covariates were
fitted together with the baseline characteristics in one model.
We examined diagnostic plots and carried out formal checks for
deviation from the proportional hazards assumption using
Schoenfeld residuals for each of the potential confounding
variables. Kaplan-Meier curves were plotted to display the
probability of survival over the study period. Analysis was
conducted using SAS (v9) software package (SAS Institute, Cary,
NC, USA).
Sub-group analysis. The above analyses were conducted on
the total cohort of patients who had an AMI at baseline. As a
subgroup analysis, longer-term fatality was assessed using only
patients with complete data on smoking status and BMI and
excluding patients with missing data (complete case analysis).
Results
In total, 2,887 incident cases of AMI occurred during 909,097
person-years of observation, giving a crude incidence rate for AMI
of 3.2 (95%CI 3.1–3.3) per 1,000 person-years. The overall mean
age of patients in the study was 68.2 years (standard deviation:
13.6 years). Compared to men, women were more likely to be
older and have a previous diagnosis of stroke, hypertension, atrial
fibrillation or heart failure (Table 1).
Mortality
Nearly half (n = 1,282, 44.4%, 95%CI 42.6–46.2) of all the
patients who had a first AMI died within five years. One fifth
(n = 589, 20.4%, 95%CI 18.9–21.9) died in the community prior
to hospitalization. The short-term mortality rate for patients who
had a first AMI was 27.1% (95% CI 25.5–28.7; n = 783). Of the
783 patients who died within 30 days, 755 (96.4%; 95% CI 95.1–
97.7) died from a CHD-related cause and were excluded from
subsequent analysis.
Between 30 days and five years, 499 of the remaining 2104
patients died: (23.7%; 95%CI 21.9–25.5), of whom 355 (71.1%;
95%CI 67.1–75.1) died from a CHD-related cause. Amongst
those who survived more than 30 days, the median time to any
death was 722 (inter-quartile range (IQR) 265–1277) days, and to
death from CHD 663 (IQR 225–1212) days. Older age, history of
diabetes, stroke and heart failure at baseline were all associated
with an increased risk of longer-term death from any cause
(Table 2). Exactly the same characteristics were associated with
CHD-related deaths. Figure 1 displays Kaplan-Meier curves for
longer-term all-cause mortality stratified by age (,65, 65–74, 75+
years).
Revascularization. Overall, 159 (7.6%) patients who
survived more than 30 days had a CABG and 222 (10.6%) had
a PTCA. Ten of the 783 patients who died within 30 days of their
first AMI underwent PTCA. No-one undergoing CABG died
within 30 days of their first AMI. As an extension to the adjusted
longer-term mortality model, cardiac procedures and secondary
prevention therapy after index diagnosis (including during the first
30 days) were included as time-varying covariates. Although
having a PTCA after an AMI significantly lowered the hazard of
all-cause mortality, after adjusting for baseline characteristics and
the other time-varying covariates, both CABG and PTCA had no
significant effect (Table 3). However, a PTCA after AMI
significantly lowered the hazard of CHD-related mortality, even
after adjusting for baseline characteristics and the other time-
varying covariates. CABG had no significant effect on CHD
mortality. After PTCA, 114 (51.4%) patients had a further
diagnosis of angina, 54 (24.3%) a further hospitalization for acute
coronary syndrome and 13 (5.9%) for heart failure. After CABG,
60 (37.7%) patients had a further diagnosis of angina, 24 (15.1%) a
further hospitalization for acute coronary syndrome and 15 (9.4%)
for chronic heart failure.
Secondary preventive therapies. Of the total cohort of
patients experiencing an incident AMI and surviving 30 days,
1,294 (61.5%) were issued with at least one prescription for ACE
inhibitor therapy by their primary care practice, 1,364 (64.8%) for
a b-blocker, 1,802 (85.6) for an antiplatelet and 1,460 (69.4%) for a
statin. Some patients did not receive any secondary preventive
therapy (n= 182; 8.7%) with 37.5% receiving all four (n = 788).
The secondary prevention therapies of b-blockers and statins
prescribed after index diagnosis were associated with a reduced
risk of longer-term mortality from any cause and CHD (Table 3).
Patients who were prescribed ACE inhibitor therapy during
follow-up had a significantly increased risk of longer-term
mortality from all-causes and CHD. Anti-platelet therapy had
no significant effect on time to longer-term death. For the 1,571
patients prescribed at least one therapy (but not receiving
revascularization), 597 (38.0%) patients had a further diagnosis
of angina, 177 (11.3%) a further hospitalization for acute coronary
syndrome and 108 (6.9%) for chronic heart failure.
Baseline characteristics - revascularisation and
secondary preventive therapy. The baseline co-morbidities
of patients receiving revascularization or secondary preventive
therapies can be found in table 4. Patients receiving ACE-
inhibitors had the highest rates of heart failure, atrial fibrillation,
diabetes and angina at baseline. Patients receiving antiplatelets
had the highest rate of stroke and were also the oldest patients.
Patients receiving CABG had the highest rate of angina and
Table 1. Key baseline variables of patients with a first
diagnosis of acute myocardial infarction (n = 2,887).
Women Men p-value
Baseline
characteristics: n(%) n (%)
Total 1245 1642
Age-band: ,65 years 301 (24.2) 789 (48.1)
65–74 years 315 (25.3) 474 (28.9)
$75 years 629 (50.5) 379 (23.1) ,0.001
Deprivation 1st 122 (9.8) 189 (11.5)
quintile 2nd 234 (18.8) 319 (19.4)
3rd 321 (25.8) 433 (26.4)
4th 296 (23.8) 362 (22.1)
5th 272 (21.9) 339 (20.7) 0.47
Co-morbidity Angina 256 (20.5) 363 (22.1) 0.34
(yes vs no): Diabetes 136 (10.9) 190 (11.6) 0.63
CKD 19 (1.5) 24 (1.5) 1.00
Stroke 150 (12.1) 149 (9.1) 0.01
PVD 95 (7.6) 125 (7.6) 1.000
Hypertension 454 (36.5) 385 (23.5) ,0.001
AF 94 (7.6) 64 (3.9) ,0.001
Heart failure 161 (12.9) 129 (7.9) ,0.001
CKD= chronic kidney disease; PVD=peripheral vascular disease; AF = atrial
fibrillation.
doi:10.1371/journal.pone.0026573.t001
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Table 2. Factors affecting longer-term (31 days to 5 years) mortality (N = 2104).
All cause mortality CHD mortality
Baseline
characteristic n (%)
Unadjusted hazard
ratios (95% CI)
Adjusted hazard
ratios (95% CI) n (%)
Unadjusted hazard
ratios (95% CI)
Adjusted hazard
ratios (95% CI)
Sex Female 243 (28.6) 1.00 1.00 177 (20.8) 1.00 1.00
Male 256 (20.4) 0.68 (0.57, 0.81) { 1.09 (0.90, 1.32) 178 (14.2) 0.65 (0.53, 0.80) { 1.03 (0.83, 1.29)
Age-band: ,65 years 95 (9.9) 1.00 1.00 61 (6.4) 1.00 1.00
65–74 years 121 (20.8) 2.22 (1.70, 2.90) { 2.12 (1.61, 2.78) { 88 (15.1) 2.51 (1.81, 3.48) { 2.36 (1.70, 3.28) {
$75 years 283 (50.3) 6.78 (5.37, 8.56) { 6.25 (4.87, 8.02) { 206 (36.6) 7.59 (5.70, 10.11) { 6.83 (5.04, 9.25) {
Deprivation 1st 56 (23.1) 1.00 1.00 37 (15.2) 1.00 1.00
quintile (vs 1st) 2nd 107 (26.0) 1.18 (0.85, 1.63) 1.15 (0.83, 1.58) 69 (16.8) 1.15 (0.77, 1.71) 1.13 (0.76, 1.69)
3rd 114 (20.6) 0.90 (0.65, 1.24) 0.90 (0.65, 1.24) 84 (15.2) 1.00 (0.68, 1.47) 1.01 (0.68, 1.48)
4th 119 (25.5) 1.13 (0.82, 1.55) 1.17 (0.85, 1.61) 94 (20.2) 1.35 (0.92, 1.97) 1.42 (0.97, 2.09)
5th 103 (24.0) 1.05 (0.76, 1.46) 1.12 (0.81, 1.56) 71 (16.5) 1.10 (0.74, 1.63) 1.16 (0.78, 1.73)
Co-morbidity Angina 121 (27.3) 1.24 (1.01, 1.52) * 0.96 (0.78, 1.19) 95 (21.4) 1.41 (1.11, 1.78) { 1.07 (0.84, 1.37)
(yes vs no) Diabetes 80 (35.9) 1.73 (1.36, 2.20) { 1.83 (1.43, 2.34) { 63 (28.3) 1.95 (1.49, 2.56) { 2.02 (1.53, 2.68) {
CKD 10 (38.5) 1.98 (1.06, 3.69) * 1.76 (0.93, 3.34) 8 (30.8) 2.21 (1.10, 4.45) * 1.86 (0.91, 3.81)
Stroke 80 (46.5) 2.50 (1.97, 3.17) { 1.73 (1.35, 2.22) { 61 (35.5) 2.69 (2.04, 3.55) { 1.88 (1.41, 2.50) {
PVD 45 (32.6) 1.46 (1.07, 1.98) * 1.19 (0.87, 1.62) 36 (26.1) 1.66 (1.17, 2.34) { 1.31 (0.93, 1.86)
Hypertension 156 (26.5) 1.19 (0.99, 1.44) 0.80 (0.65, 0.98) * 114 (19.4) 1.24 (0.99, 1.55) 0.78 (0.62, 0.99) *
AF 51 (50.5) 2.76 (2.07, 3.69) { 1.36 (1.00, 1.86) 33 (32.7) 2.46 (1.72, 3.53) { 1.17 (0.80, 1.71)
Heart failure 70 (54.7) 3.28 (2.55, 4.23) { 1.69 (1.28, 2.22) { 54 (42.2) 3.57 (2.67, 4.77) { 1.80 (1.31, 2.46) {
*p,0.05;
{p,0.01;
{p,0.001.
CHD= coronary heart disease; CKD= chronic kidney disease; PVD=peripheral vascular disease; AF = atrial fibrillation.
doi:10.1371/journal.pone.0026573.t002
Figure 1. Survival function for all-cause longer term (31 days to 5 years) mortality after first acute myocardial infarction by age
group (n=2104).
doi:10.1371/journal.pone.0026573.g001
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peripheral vascular disease with patients prescribed b-blockers
having the highest rate of hypertension.
Subgroup analysis
An analysis was performed on the subgroup with complete
smoking and BMI data to assess whether these risk factors had an
effect on mortality after first AMI (i.e. a complete case analysis).
Nine hundred and two patients (31.2%) had incomplete smoking
data at the time of their index event and 904 (31.3%) patients had
incomplete BMI data; these subjects were excluded from the
secondary analysis where smoking and BMI were included as
baseline factors. Smokers had an increased risk of longer-term all-
cause (AHR: 1.43 95%CI 1.05–1.95) and CHD-related mortality
(AHR: 1.69 95%CI 1.16–2.46), compared with non-smokers. Ex-
smokers were no more likely to have longer-term mortality after
first AMI than non-smokers (AHR: 0.96 95%CI 0.69–1.35).
Obese patients had a significantly higher hazard of all-cause
mortality compared to non-obese patients (AHR: 1.39 95%CI
1.01–1.90).
Discussion
Summary of main findings
Nearly half of all the patients in this large community-based
cohort who had a first AMI died within five years. More than a
quarter of patients died within 30 days of having their first AMI,
mostly (96.6%) from CHD causes. Patients who survived to at least
30 days after their first AMI and who received PTCA or some (but
not all) secondary preventive treatments after the diagnosis of
AMI, had important reductions in their risk of subsequent
mortality. The risk of longer-term mortality amongst smokers
and the obese was substantially increased, independent of other
risk factors such as socioeconomic status and age.
Strengths and limitations of this work
A major strength of our study was the use of a large incident
cohort of patients identified using both primary and secondary
care records. Other strengths were the length of follow-up, the
availability of data on a number of characteristics from a
Table 3. The effect of coronary revascularization procedures and secondary prevention therapy during follow-up (as time-varying
covariates) on longer-term (31 days to 5 years) mortality.
All-cause mortality CHD mortality
Time-varying
covariate n/N (%)
Unadjusted hazard
ratios (95% CI)
Adjusted hazard
ratios (95% CI) * n/N (%)
Unadjusted hazard
ratios (95% CI)
Adjusted hazard
ratios (95% CI) *
CABG 10/159 (6.3) 0.88 (0.75, 1.04) 0.96 (0.81–1.14) 9/159 (5.7) 0.44 (0.22, 0.85) { 0.69 (0.35–1.35)
PTCA 17/222 (7.7) 0.86 (0.75, 0.99) { 0.97 (0.84–1.12) 10/222 (4.5) 0.27 (0.15, 0.51) 1 0.49 (0.26–0.93) {
ACE inhibitors 279/1294 (21.6) 1.06 (0.97, 1.16) 1.13 (1.02–1.24) { 211/1294 (16.3) 1.55 (1.25, 1.93) 1 1.74 (1.38–2.21) 1
b-blockers 207/1364 (15.2) 0.81 (0.74, 0.88) 1 0.89 (0.80–0.98) { 139/1364 (10.2) 0.41 (0.33, 0.51) 1 0.58 (0.46–0.74) 1
Anti-platelets 384/1802 (21.3) 0.98 (0.86, 1.11) 1.14 (0.99–1.32) 276/1802 (15.3) 1.03 (0.80, 1.34) 1.28 (0.96–1.71)
Statins 195/1456 (13.3) 0.76 (0.69, 0.83) 1 0.81 (0.72–0.90) 1 143/1456 (9.8) 0.41 (0.33, 0.52) 1 0.60 (0.47–0.77) 1
*Adjusted for baseline characteristics and all time varying covariates.
{p,0.05;
{p,0.01;
1p,0.001.
ACE = angiotensin converting enzyme; AMI = acute myocardial infarction; CHD= coronary heart disease; CABG= coronary artery bypass grafting; PTCA=percutaneous
transluminal coronary angioplasty.
doi:10.1371/journal.pone.0026573.t003
Table 4. Co-morbidity of patients receiving revascularization or secondary preventive therapy (yes vs. no).
Angina
n (%)
Diabetes
n (%)
CKD
n (%)
Stroke
n (%)
PVD
n (%)
Hypertension
n (%)
Atrial fibrillation
n (%)
Heart failure
n (%)
CABG Yes 58 (36.5) 21 (13.2) 2 (1.3) 10 (6.3) 16 (10.1) 45 (28.3) 5 (3.1) 4 (2.5)
No 386 (19.8) 202 (10.4) 24 (1.2) 162 (8.3) 122 (6.3) 543 (27.9) 96 (4.9) 124 (6.4)
PTCA Yes 40 (16.7) 23 (9.6) 4 (1.7) 4 (1.7) 12 (5.0) 56 (23.4) 0 (0.0) 3 (1.3)
No 404 (21.7) 200 (10.7) 22 (1.2) 168 (9.0) 126 (6.8) 532 (28.5) 101 (5.4) 125 (6.7)
ACE-Inhibitors Yes 296 (22.9) 185 (14.3) 16 (1.2) 99 (7.7) 92 (7.1) 412 (31.8) 56 (4.3) 88 (6.8)
No 148 (18.3) 38 (4.7) 10 (1.2) 75 (9.0) 46 (5.7) 176 (21.7) 45 (5.6) 40 (4.9)
b-blockers Yes 304 (22.3) 142 (10.4) 8 (1.1) 80 (5.9) 77 (5.6) 395 (29.0) 45 (3.3) 52 (3.8)
No 140 (18.9) 81 (10.9) 18 (1.3) 92 (12.4) 61 (8.2) 193 (26.1) 56 (7.6) 76 (10.3)
Anti-platelets Yes 402 (22.3) 200 (11.1) 21 (1.2) 144 (8.0) 125 (6.9) 513 (28.5) 70 (3.9) 100 (5.5)
No 42 (13.9) 23 (7.6) 5 (1.7) 28 (9.3) 13 (4.3) 75 (24.8) 31 (10.3) 28 (9.3)
Statins Yes 333 (22.9) 165 (11.3) 14 (1.0) 98 (6.7) 97 (6.7) 405 (27.8) 48 (3.3) 69 (4.7)
No 111 (17.1) 58 (9.0) 12 (1.9) 74 (11.4) 41 (6.3) 183 (28.2) 53 (8.2) 59 (9.1)
doi:10.1371/journal.pone.0026573.t004
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representative sample of community dwelling individuals prior to
their first AMI and the novel database linkage that allowed the
use of data recorded in secondary as well as primary care, and
cause of death data from death certificates. By combining
primary and secondary care data, we were able to identify and
exclude patients who were likely to have had a previous history of
AMI before the index episode. The use of outcome data from
secondary care and GROS also allowed us to follow up
individuals even if they left their primary care practice after the
index episode, since all hospitalizations (in Scotland) and
mortality data were available to us.
Although we were able to include a number of co-morbidities
and risk factors in our models, some clinical, electrocardio-
graphic, and enzyme or biomarker characteristics used to help
guide triage and immediate management decisions were not
available. Other limitations include absence of information
about the use of thrombolytics and other effective cardiac
medications used in hospital. We did not have any details of the
criteria used when recording an episode of AMI, or of any
investigations used to make the diagnosis. It is possible that
different criteria were used for different groups within the
population (especially for events leading to death before
hospitalization), although the strong relationship between
baseline characteristics and fatal outcome provides some face
validity for the index diagnosis. As some co-morbidities were
relatively uncommon, such as chronic kidney disease, we
sometimes lacked power to reliably detect statistical significant
relationships that may exist.
Considering the findings from this work in relation to
other published literature
In terms of its baseline characteristics, our community-based
cohort differed in several ways from previous cohorts used for
prognostic studies. Although our cohort had a similar age and sex
profile as a cohort of patients admitted to acute care general
hospitals with AMI in Worcester, USA between 1995 and 2001
(68 years vs. 69 years; male patients 58% vs. 58% respectively) [9],
the medical history profile of the two cohorts was quite different.
For example, 31% of individuals in our study had hypertension,
11% diabetes, and 11% heart failure, compared with 69%, 32%
and 22% respectively in the Worcester cohort. Rates of CABG
and PTCA found in our cohort were lower to rates reported
amongst survivors in the Worcester cohort (CABG: 7.6% vs
11.2%; PTCA: 10.6% vs. 35.5%) [17]. This may reflect lower
rates of revascularization procedures performed in Scotland at the
time, which may have contributed to higher subsequent mortality.
Another large global cohort of patients with acute coronary
syndrome identified in cardiac clinics included patients with a
prior history of AMI (the GRACE trial) and has subsequently been
used to calculate a hospital mortality risk score [18]. The GRACE
cohort had a similar age profile (65.0 vs. 68.2 years), but a higher
proportion of males (66.0% vs. 56.8%) than our cohort. Our short-
term fatality of 27.1% was higher than the 19.9% found using a
Scottish national hospital based cohort [8], but similar to fatality
rates found in a cohort of Swedish first AMI patients, which also
included pre-hospital deaths (23.5% to 23.8%) [19]. Our longer-
term mortality rates were similar to those found from Scottish
national datasets (23.7% vs. 23.3%) [8].
Our population presenting with a first AMI also differed from
the general Scottish population [20]. For instance the rate of
diabetes in our population was higher (women: 10.9% vs. 3.7%;
men: 11.6% vs. 3.8%) [21]. Rates of hypertension were higher for
women (36.5% vs. 33.0%) but lower for men (23.5% vs. 31.7%).
Smoking rates in our cohort (women: 38.5% and men: 49.5%)
were much higher than the general population (2003 - women:
28% and men: 29%). In contrast, rates of obesity (women: 17.1%
and men: 15.4%) were lower than the general population (2003 -
women: 26% and men: 22.4%) although this is possibly due to the
older age of our population.
Differences between these other cohorts and ours – which
included as far as possible every incident AMI over five years
amongst nearly a quarter of a million people living in Scotland –
highlight the need for caution when considering the application in
community settings of risk scores or guidelines developed in other
settings [18,22]. However, it is still probable that the impact of risk
factors and secondary prevention on subsequent mortality in our
cohort would apply equally, if not more so, in populations without
AMI and those outside of Scotland [10].
Our finding of a significant association with smoking at
baseline and an increased risk of longer-term all-cause and
CHD death does not support the previously observed ‘paradox
of smokers’ surviving longer post-AMI than non-smokers [23].
A number of baseline co-morbidities were associated with
subsequent outcome. The association in our study between
diabetes at baseline and subsequent long-term fatality is in line
with previous findings from a recent primary care cohort of
people with CHD [24] and our work using these linked data
[10]. Contrary to previous findings, we observed an increased
risk of longer-term mortality among those receiving ACE
inhibitors (AHR 1.13, 95%CI 1.02–1.24 vs. relative risk 0.87,
0.81–0.94 [25]) and no significant effects among those receiving
anti-platelets (AHR 1.14, 0.99–1.32 vs. risk ratio 0.79, 0.74–
0.84 [26]). It is plausible that these results could be due to
confounding by indication. With a relatively poor prognosis [27]
and an increased likelihood of subsequent all-cause and CHD-
related mortality being found for this cohort, heart failure was
found in proportionally more patients receiving ACE-inhibitors
than those that didn’t receive the therapy. For other therapies,
proportionally more patients did not have a history of heart
failure and a better prognosis. Although we have attempted to
account for markers of disease severity such as patient’s baseline
characteristics, further work is required to identify markers of
disease severity from routinely collected datasets, which can be
used to take into account the propensity to be prescribed drugs
or given an intervention.
Conclusions
Our study has provided an innovative opportunity to consider
the longer-term mortality risk observed in routine clinical practice
amongst a community-based incident cohort of people who
experienced their first AMI in Scotland. It is encouraging that the
coronary procedure PTCA, and pharmacological secondary
prevention therapies were found to be strongly associated with
an important reduced risk of subsequent death, although an
opportunity exists for optimization of medical therapy as not all
patients received these interventions. In addition, smoking and
being obese at baseline were associated with an increased
likelihood of mortality, independent of other baseline character-
istics. Thus, it is likely (with the proviso that these data can only
show association rather than causation of risk factors and outcome)
that the provision of smoking cessation, advice on diet (for obese
patients) and optimal medical therapy are crucial for reducing
mortality in all patients after AMI. Our study also demonstrates
that linked clinical datasets such as this one provides an important
opportunity to study prognosis quickly and cost-effectively, and
assess (all be it without being able to ‘‘trump’’ trial findings) the
likely generalizability of trial findings when implemented into
routine care.
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